Functional Impairment and Painful Physical Symptoms in Patients with Major Depressive Disorder Treated with Antidepressants: Real-World Evidence from the Middle East

Table 3: The results of MMRM analyses: Factors associated with SDS total scores during follow-up.

Parameter	Parameter Estimate	Standard Error	P-Value
Intercept	9.35	1.67	<0.001
Age	-0.02	0.02	0.338
Female (vs. male)	-0.31	0.39	0.421
CGI	-0.18	0.39	0.642
QIDS-SR₁₆ Score at Baseline	-0.31	0.06	<0.001
SSI-Pain Score at Baseline	0.10	0.05	0.030
SDS Total Score at Baseline	0.31	0.03	<0.001
Duloxetine (vs. SSRI)^a	-0.25	0.64	0.697
Weeks (vs. Week 8)^a
Week 16	-4.41	0.44	<0.001
Week 24	-5.49	0.48	<0.001
Weeks*Treatment^a
Duloxetine at Week 16	-0.58	0.58	0.324
Duloxetine at Week 24	-1.58	0.65	0.015

^a As the model included the interaction term between treatment and time (weeks), the interpretation of the coefficients of treatment and time is not straightforward. The least squares mean of the SDS total score at each post-baseline visit by treatment cohorts was further estimated and presented in (Fig. 1). Abbreviations: QIDS-SR₁₆, 16-item Quick Inventory of Depressive Symptomatology Self-Report; SDS, Sheehan Disability Scale; SSI, Somatic Symptom Inventory; SSRI, Selective Serotonin Reuptake Inhibitor